Zepbound is one of the most effective weight loss medications available. In clinical trials, people taking the highest dose lost an average of 20.9% of their body weight over 72 weeks, which translates to roughly 50 pounds for many participants. That level of weight loss was previously only achievable through bariatric surgery.
Weight Loss by Dose
Zepbound (tirzepatide) comes in three target doses, and the amount of weight you lose depends on which dose you work up to. In the landmark SURMOUNT-1 trial, which followed over 2,500 adults for 72 weeks, the results broke down like this:
- 5 mg dose: 15% average body weight loss
- 10 mg dose: 19.5% average body weight loss
- 15 mg dose: 20.9% average body weight loss
- Placebo: 3.1% average body weight loss
These are averages, so some people lost more and some lost less. But even the lowest dose delivered roughly five times the weight loss seen with diet and exercise alone (the placebo group). The difference between the 10 mg and 15 mg doses was relatively small, which means many people get strong results without needing the highest dose.
How Zepbound Compares to Wegovy
The question most people really want answered is how Zepbound stacks up against Wegovy (semaglutide), the other major weight loss injection. A head-to-head trial called SURMOUNT-5 tested them directly against each other, and Zepbound came out ahead by a significant margin.
Participants on Zepbound lost an average of 20.2% of their body weight (about 50 pounds), while those on Wegovy lost 13.7% (about 33 pounds). That’s 47% more relative weight loss with Zepbound. The gap was even more dramatic at the higher end: 31.6% of Zepbound users lost at least a quarter of their body weight, compared to 16.1% on Wegovy. Both medications work, but Zepbound consistently produces greater results in clinical settings.
Why It Works Differently
Zepbound targets two hormone pathways instead of one, which is the main reason it outperforms older weight loss drugs. Wegovy and similar medications activate only the GLP-1 pathway, which slows digestion and reduces appetite. Zepbound activates both GLP-1 and a second pathway called GIP, which improves how your body processes fat and enhances the appetite-suppressing signal in the brain.
This dual approach also has a practical benefit for tolerability. GLP-1 activation is what causes the nausea many people experience on these drugs. Because Zepbound leans more heavily on the GIP pathway, it can deliver strong weight loss effects without requiring as much GLP-1 stimulation. That doesn’t eliminate side effects entirely, but the design helps balance efficacy with how the drug feels day to day.
What the Timeline Looks Like
Weight loss on Zepbound begins within the first few weeks, though the early phase is intentionally slow. You start on a low dose (2.5 mg) for the first four weeks, which is a tolerability period rather than a therapeutic dose. Your doctor gradually increases the dose every four weeks until you reach your target.
Most of the significant weight loss happens during the first 40 to 50 weeks, with results continuing to accumulate through week 72 in clinical trials. The trajectory isn’t linear. Early on, you might lose a few pounds per month as your dose ramps up, with the pace accelerating as you reach higher doses and then gradually plateauing as you approach your new stable weight.
What Happens if You Stop
This is the part most people don’t hear about upfront, and it matters. Zepbound is designed as a long-term medication, and stopping it leads to significant weight regain for most people.
The SURMOUNT-4 trial studied what happened when people who had been losing weight on Zepbound for 36 weeks were switched to a placebo. One year after stopping, 82% of those participants regained more than a quarter of the weight they had lost. Nearly a quarter of them regained 75% or more of their lost weight. Only a small fraction, about 1 in 6, kept most of the weight off without the drug.
This doesn’t mean the medication failed. It means obesity is a chronic condition that, for most people, requires ongoing treatment. The same pattern holds for blood pressure medications and cholesterol drugs. If the underlying biology hasn’t changed, stopping the medication brings the numbers back up. Going into treatment with that understanding helps set realistic expectations.
Common Side Effects
Digestive side effects are the most frequent complaint. In the SURMOUNT-5 trial, about 44% of Zepbound users experienced nausea, 27% had constipation, and 24% dealt with diarrhea. These effects tend to be worst during the dose escalation period and often improve as your body adjusts. The slow dose ramp-up schedule exists specifically to minimize these issues.
For most people, the side effects are manageable and temporary. Eating smaller meals, avoiding high-fat foods, and staying hydrated all help. Some people find certain doses are their sweet spot, where weight loss remains strong but side effects are tolerable, and work with their doctor to stay there rather than pushing to the maximum dose.
Who Can Get a Prescription
The FDA approved Zepbound for adults with a BMI of 30 or higher, which is the clinical threshold for obesity. You can also qualify with a BMI of 27 or higher if you have at least one weight-related health condition, such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. It’s prescribed alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.
Zepbound is not approved for people who simply want to lose a few pounds for cosmetic reasons. The BMI thresholds exist because the medication carries real side effects, and the risk-benefit calculation favors people whose weight poses meaningful health risks. Insurance coverage, when available, typically requires documentation of these same criteria.